Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacies Concerned Part D Donut Hole Discounts Could Add To Costs

Executive Summary

While the National Community Pharmacists Association welcomes provisions in the health care reform law to close the Medicare Part D coverage gap in principle, the group is wary of the potential for the system to add new costs for independent community pharmacists

You may also be interested in...



Chart: Timeline Of Pharma Provisions In Health Care Reform

It is arranged in seven sections, with provisions in each arranged chronologically. If the date is listed as "upon enactment," it means no date was specified in the statute; however, in many cases, regulatory agencies may need to issue guidance or regulations before the provision can be implemented. The information is based on the two health care reform bills: H.R. 3590, which contains the bulk of the reform language, passed the Senate in December, passed the House March 21, and was signed into law March 23; and subsequent fixes in the budget reconciliation bill, H.R. 4872, which cleared the House March 21 and Senate March 25, and the president was expected to sign March 30. The chart also borrows from a comparison chart of pharma provisionsin the two bills by Ian Spatz of Manatt, Phelps & Phillips.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel